Skip to main content
Platinum Based Chemotherapy or Observation in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Sponsor: ECOG

The main purpose of this study is to compare the usual approach (i.e. no more treatment), to any good and bad effects of getting more treatment with a platinum-based chemotherapy (cisplatin or carboplatin), after surgery.

Platinum agents (cisplatin or carboplatin) are already FDA-approved to be used in patients with stage IV breast cancers, but are usually not used in patients with early forms of breast cancer. The addition of a platinum-based chemotherapy to the usual approach (i.e. no other treatment) could prevent the cancer from returning (metastatic recurrence), but it could also cause side effects.

This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the study approach should improve how long one is able to live, free of cancer, by 24 months or more, compared to the usual approach.

ClinicalTrials.gov full clinical trial description

Researchers

  • Principal investigator:
    • Qun Dai, MD

  • Secondary investigators:
    • Alexander Bershadskiy, MD
    • Alisa Sokoloff, MD
    • Marcel A. Odaimi, MD
    • Meekoo Dhar, MD
    • Terenig O. Terjanian, MD

  • Coordinators:

Locations

Staten Island University Hospital North Campus
475 Seaview AveStaten Island, NY 10305